Precertification Required on Part B New Injectables

Amerigroup* is adding the following new injectable drugs to the 2015 Medicare Advantage list of Part B Injectables / Infusible requiring precertification. As of October 1, 2015 providers must call for precertification of these drugs.

1. Entyvio (vedolizumab): a monoclonal antibody that is a specific integrin receptor antagonist used for the treatment of moderate to severe active Crohn’s disease and ulcerative colitis in adult patients. (C9026)
2. Cyramza (Ramucirumab): used in the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression during or after treatment with fluoropyrimidine-or platinum-containing chemotherapy (C9025).

This update to the 2015 precertification requirement applies to all the following Medicare Advantage plans.

53993WPSENMB 06/10/15

*In New Mexico, Amerigroup Community Care of New Mexico, Inc. In Texas, Amerigroup members in the Medicaid Rural Service Area are served by Amerigroup Insurance Company; all other Amerigroup members are served by Amerigroup, Texas, Inc. In Washington, Amerigroup Washington, Inc.

Amerivantage is a DSNP plan with a Medicare contract and a contract with the State Medicaid program. In New Mexico: Amerivantage is an HMO with a Medicare contract. Enrollment in Amerivantage depends on contract renewal.